-
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both encouraging news and a...
IN THE SPOTLIGHT
-
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions. AI has evolved from early consumer tools... -
Small Cell SMASHERS Fireside Chat with Dr. Eric Singhi
Eric Singhi, MD, assistant professor, University of Texas MD Anderson Cancer Center, joined us to discuss the role of community and support in people with small cell lung cancer... -
Explaining BiTE® Therapy
A bi-specific T-cell engager (BiTE®) is a new type of engineered molecule used for the treatment of cancer. These molecules harness and activate T-cells, which are involved in the... -
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting... -
SCLC Virtual Meetup
SCLC patients/survivors - Join us the 3rd Wednesday of every month to c onnect with others who share common experiences and build your community. Register in advance for this... -
Small Cell SMASHERS Fireside Chat with Dr. Misty Shields
This special edition of the Small Cell SMASHERS features Misty Shields, MD, PhD, as a guest instead of her usual role as host. Dr. Shields is a thoracic medical oncologist... -
Small Cell SMASHERS Fireside Chat: Who's Up Next?
Small Cell SMASHERS Fireside Chat with Dr. Laura Alder Join us for a YouTube Live on Friday, March 20, with Laura Alder, MD, Assistant Professor of Medicine in the Division of... -
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000... -
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects...
Phosphorylation-dependent remodeling of the XIAP IRES by hnRNPA1
Small Cell Lung Cancer Treatments by Stage
When Small Cell Lung Cancer Hides from Immune Cells, Blood Vessels May Hold the Key
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer
Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study
Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study
Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study
Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study
Quizzes
When Small Cell Lung Cancer Hides from Immune Cells, Blood Vessels May Hold the Key
Reviewing the IMforte Phase 3 Data in Extensive Stage Small Cell Lung Cancer
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both encouraging news and a sobering reminder that our work is far from over.The Big Picture Shows Real ProgressLet’s start with the good news. We have made significant strides in cancer care over the past three decades. Since 1991, the cancer death rate has dropped by 34%. This translates to approximately 4.8 million…
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions.AI has evolved from early consumer tools (like autocorrect on phones, customer service chatbots, and personalized shopping recommendations) to advanced systems with the potential to revolutionize biomedical discovery and patient care. While there is tremendous excitement around AI, there is also a critical need to use it responsibly.Researchers are actively…
Small Cell SMASHERS Fireside Chat with Dr. Eric Singhi
Small Cell SMASHERS Fireside Chat with Dr. Eric Singhi
Eric Singhi, MD, assistant professor, University of Texas MD Anderson Cancer Center, joined us to discuss the role of community and support in people with small cell lung cancer.Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting healthy tissue. But sometimes, the checks and balances get confused and stop the immune system from doing what’s right—such as killing tumor cells. Tumor cells are good at confusing the immune system because they originate from our healthy cells. They can often avoid detection by immune cells. Through several…
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused on multidisciplinary research aiming to leverage the immune system to improve outcomes for cancer patients, including several exciting areas of growth in lung cancer-directed immunotherapy.Tumor Imaging is Growing More Powerful Advanced imaging techniques are poised to change how we understand and treat…
The Future of Lung Cancer Starts Here
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects, helping to build a robust pipeline of discoveries in early detection, treatment innovation, and health equity.Once again, LUNGevity is ready to open our annual grant cycle in 2026 with five research programs designed to address the most pressing challenges in lung cancer care. In addition, these grants ensure the…
Biggest News from Berlin: Research Highlights from ESMO
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000 attendees from over 100 countries, this meeting gathered an international audience of clinicians, researchers, patient advocates, and representatives from the healthcare industry to discuss cutting-edge cancer research and share practice-changing clinical trial data. We saw data from studies that aim to build upon…
Small Cell SMASHERS Fireside Chat with Dr. Misty Shields
Small Cell SMASHERS Fireside Chat with Dr. Misty Shields
This special edition of the Small Cell SMASHERS features Misty Shields, MD, PhD, as a guest instead of her usual role as host. Dr. Shields is a thoracic medical oncologist, assistant professor of clinical medicine, adjunct assistant professor of medical and molecular genetics, and associate member of experimental and developmental therapeutics at Indiana University School of Medicine and Indiana University Health Physicians. Dr. Shields discusses her American Society of Clinical Oncology (…
Small Cell SMASHERS Fireside Chat with Dr. Trudy Oliver
Small Cell SMASHERS Fireside Chat with Dr. Trudy Oliver
In November, Trudy Oliver, PhD, professor of pharmacology and cancer biology at Duke University School of Medicine and Duke Cancer Institute, discussed the origins of small cell lung cancer (SCLC) and its impact on plasticity.Moderated by Dr. Misty Shields, Indiana University School of Medicine, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs for SCLC.
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum—from early detection to treating advanced disease.“Today’s research is tomorrow’s cure. If we want to see continued breakthroughs and advancements in lung cancer, we must secure a strong pipeline of researchers dedicated to improving outcomes for people with lung cancer,” said Upal Basu Roy, PhD, MPH, Executive Director…
Explaining BiTE® Therapy
Explaining BiTE® Therapy
A bi-specific T-cell engager (BiTE®) is a new type of engineered molecule used for the treatment of cancer. These molecules harness and activate T-cells, which are involved in the body’s immune response, to attack tumor cells. There is currently one FDA-approved BiTE® therapy treatment for targeting small cell lung cancer (SCLC).The video below was created to give you clear, easy-to-understand information about bi-specific T-cell engagers, so you can feel more informed and prepared as you…
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung cancer diagnosis. From groundbreaking early detection efforts to life-extending treatments, each step forward represents years of collaboration between researchers, patients, and others in the lung cancer community.Today, LUNGevity celebrates five exciting areas of progress that highlight the incredible strides made…
Veteran Voices: Surgery to Survivorship at the VA
Veteran Voices: Surgery to Survivorship at the VA
Last November, Michael O’Donnell was at the Dallas VA during Lung Cancer Awareness Month. It’s where he receives treatment for his lung cancer, but on this specific day, he was joined by LUNGevity staff to talk with veterans about screening.“My job was easy. I was at a table with Kristi Griffith [LUNGevity’s Survivorship Navigator] so that I could answer questions as someone who uses the VA to get treated for lung cancer,” says Michael. Michael is a veteran of the Vietnam War and uses the…
Small Cell SMASHERS Fireside Chat: Dr. Toby Campbell
Small Cell SMASHERS Fireside Chat: Dr. Toby Campbell
In this Facebook Live on Tuesday, October 14, Toby Campbell, MD, MS, thoracic medical oncologist and chief of palliative care at the University of Wisconsin Health, discussed palliative care in small cell lung cancer.Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.
FDA Approves First Maintenance Treatment for ES-SCLC
FDA Approves First Maintenance Treatment for ES-SCLC
On October 2, 2025, the US Food and Drug Administration (FDA) announced the approval of the combination treatment of lurbinectedin (Zepzelca®) plus atezolizumab (Tecentriq®) as the first maintenance (ongoing) therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). This approval is for patients who are currently benefiting from initial treatments, such as atezolizumab or atezolizumab plus chemotherapy. Atezolizumab is an immunotherapy that blocks the PD-L1 protein…
Small Cell Lung Cancer: Not Small Anymore
Small Cell Lung Cancer: Not Small Anymore
Read time: 3 minutes.Small cell lung cancer (SCLC) research continues to progress at an unprecedented rate. Exciting news emerged from the 2025 World Congress on Lung Cancer, with six studies showing how innovative therapies have the potential to give people with lung cancer better outcomes and longer survival than ever before.After decades with little treatment progress, it was remarkable to see an entire session dedicated to the treatment of newly diagnosed extensive-stage SCLC (ES-SCLC) (…
Small Cell SMASHERS Fireside Chat: Dr. Sonam Puri
Small Cell SMASHERS Fireside Chat: Dr. Sonam Puri
In this Facebook Live from September 30, Sonam Puri, MD, Department of Thoracic Oncology at H. Lee Moffitt Cancer Center, discusses the importance of real-world data for treating small cell lung cancer.Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.
Small Cell SMASHERS Fireside Chat: Kim Lowery Walker
Small Cell SMASHERS Fireside Chat: Kim Lowery Walker
In this Facebook Live from August 22, we learned about integrative medicine from Kim Lowery Walker, MBA, LCSW, Integrative Psycho-Oncology Program Manager and oncology therapist at Inova Peterson Life with Cancer.Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.
6 Tips for Managing Scanxiety
6 Tips for Managing Scanxiety
Read time: 4 minutes.Scanxiety is a term used for the anxiety someone feels as a medical exam, like an MRI or CT scan, approaches. It can come with feelings of dread or worry, as well as “what if” thoughts focused on receiving bad news, like the return or growth of a cancerous tumor. Scanxiety can be intense and intrusive, and you might find it difficult to focus on other thoughts or tasks. Many people, especially those who did not experience anxiety prior to their diagnosis, might feel…
Why Do Some People Who Have Never Smoked Get Lung Cancer?
Why Do Some People Who Have Never Smoked Get Lung Cancer?
As tobacco use has declined in recent years, we have seen a new demographic of lung cancer patients emerge. Lung cancer in individuals who have never smoked (LCINS) is becoming more common. These people are often younger women with no history of tobacco exposure.Researchers are working to understand the needs of this growing population by identifying other risk factors for lung cancer, such as family history and environmental exposures. They are also studying the molecular underpinnings of this…
Panelists Discuss New Advances from ASCO 2025
Panelists Discuss New Advances from ASCO 2025
The publication OncLive convened a panel of experts to break down the SCLC news from the ASCO conference held in June 2025. Panelists discussed strategies for treating limited-stage (LS-SCLC) and extensive-stage (ES-SCLC) small cell lung cancer, including:Integration of durvalumab in LS-SCLCNew first-line chemoimmunotherapy regimens in ES-SCLCMaintenance approaches such as atezolizumab plus lurbinectedin and durvalumab plus tarlatamab (DeLLphi-305)The promising future role of agents including T…